Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 12/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | GRN | P28799 | 2/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203163 | 0.81 | FYN (0.46) | FYNGRK5KDM4AKDM5AKDM4C | |
| SCHEMBL12850753 | 0.71 | TNF (0.51) | TGFBR1 | |
| SCHEMBL21083379 | 0.71 | TGFBR1 (0.52) | FYNTGFBR1 | |
| SCHEMBL27261942 | 0.68 | LDHA (0.50) | KDM4AKDM5AKDM4CKDM5BKCNH2 | |
| SCHEMBL23872989 | 0.68 | GRN (0.45) | FYNTGFBR1GRNSORT1 | |
| SCHEMBL2902453 | 0.66 | PIM1 (0.61) | FYN | |
| SCHEMBL24736890 | 0.66 | POLB (0.46) | — | |
| SCHEMBL21637243 | 0.66 | HTT (0.47) | TGFBR1 | |
| SCHEMBL21083366 | 0.65 | TGFBR1 (0.80) | TGFBR1 | |
| SCHEMBL20534023 | 0.64 | GRN (0.44) | GRNSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | FYN 403/4885GRK5 365/4885KDM4A 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.